Synonyms: | |
Status: | Approved (2002) |
Entry Type: | Small molecule |
Molecule Category: | Parent |
ATC: | N06BA09 |
UNII: | ASW034S0B8 |
InChI Key | VHGCDTVCOLNTBX-QGZVFWFLSA-N |
---|---|
Smile | |
InChI |
|
Property Name | Value |
---|---|
Molecular Formula | C17H21NO |
Molecular Weight | 255.36 |
AlogP | 3.72 |
Hydrogen Bond Acceptor | 2.0 |
Hydrogen Bond Donor | 1.0 |
Number of Rotational Bond | 6.0 |
Polar Surface Area | 21.26 |
Molecular species | BASE |
Aromatic Rings | 2.0 |
Heavy Atoms | 19.0 |
Primary Target | |
---|---|
NET |
Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
---|---|---|---|---|---|---|
Enzyme
Cytochrome P450
Cytochrome P450 family 2
Cytochrome P450 family 2D
Cytochrome P450 2D6
|
- | 2000-2000 | - | - | - | |
Ion channel
Voltage-gated ion channel
Potassium channels
Voltage-gated potassium channel
|
- | 2100 | - | - | - | |
Transcription factor
|
- | 100000 | - | - | 47 | |
Transporter
Electrochemical transporter
SLC superfamily of solute carriers
SLC06 neurotransmitter transporter family
|
- | 3-5 | 1080 | 43-1500 | - | |
Transporter
Electrochemical transporter
SLC superfamily of solute carriers
SLC21/SLCO family of organic anion transporting polypeptides
|
- | - | - | - | 16 |
Mesh Heading | Maximum Phase | Mesh ID | Reference |
---|---|---|---|
Attention Deficit Disorder with Hyperactivity | 4 | D001289 | ClinicalTrials |
Autistic Disorder | 3 | D001321 | ClinicalTrials |
Schizophrenia | 3 | D012559 | ClinicalTrials |
Neoplasms | 3 | D009369 | ClinicalTrials |
Phobia, Social | 2 | D000072861 | ClinicalTrials |
Opioid-Related Disorders | 2 | D009293 | ClinicalTrials |
Cognitive Dysfunction | 2 | D060825 | ClinicalTrials |
Sleep Apnea Syndromes | 2 | D012891 | ClinicalTrials |
Marijuana Abuse | 2 | D002189 | ClinicalTrials |
Tourette Syndrome | 2 | D005879 | ClinicalTrials |
Substance-Related Disorders | 2 | D019966 | ClinicalTrials |
Alcoholism | 2 | D000437 | ClinicalTrials |
Sleep Apnea, Obstructive | 2 | D020181 | ClinicalTrials |
Hypotension, Orthostatic | 2 | D007024 | ClinicalTrials |
Cocaine-Related Disorders | 1 | D019970 | ClinicalTrials |
Tobacco Use Disorder | 1 | D014029 | ClinicalTrials |
Orthostatic Intolerance | 1 | D054971 | ClinicalTrials |
Amphetamine-Related Disorders | 1 | D019969 | ClinicalTrials |
Diabetes Mellitus, Type 1 | 0 | D003922 | ClinicalTrials |
Parkinson Disease | 0 | D010300 | ClinicalTrials |
Resources | Reference |
---|---|
CAS NUMBER | 83015-26-3 |
ChEBI | 127342 |
ChEMBL | CHEMBL641 |
DrugBank | DB00289 |
DrugCentral | 256 |
EPA CompTox | DTXSID9044297 |
FDA SRS | ASW034S0B8 |
Human Metabolome Database | HMDB0014434 |
Guide to Pharmacology | 7118 |
PharmGKB | PA134688071 |
PubChem | 54841 |
SureChEMBL | SCHEMBL34268 |
ZINC | ZINC000001842633 |